Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer

Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer

Bibliographic Details
Main Authors:	L.M. Spring, H. Han, E. Hamilton, H. Irie, C.A. Santa-Maria, J. Reeves, P. Pan, M. Shan, Y. Tang, J.R. Graham, S. Hazard, L.W. Ellisen, S.J. Isakoff
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621001831

Similar Items

Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review
by: Tao M, et al.
Published: (2020-12-01)

Niraparib in ovarian cancer: results to date and clinical potential
by: Davide Caruso, et al.
Published: (2017-09-01)

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
by: Mirza, Mansoor R., et al.
Published: (2016)

Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress
by: Vladimir Bezrookove, et al.
Published: (2021-08-01)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
by: Stephanie Jonuscheit, et al.
Published: (2021-05-01)

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
by: Pietro Paolo Vitiello, et al.
Published: (2021-01-01)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
by: Quisette P. Janssen, et al.
Published: (2020-01-01)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
by: Byrski T, et al.
Published: (2012-04-01)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
by: Byrski T, et al.
Published: (2011-06-01)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
by: Yan H, et al.
Published: (2020-12-01)

Rapid and temporary improvement of depression and anxiety observed following niraparib administration: a case report
by: Benjamin E. Jewett, et al.
Published: (2020-04-01)

Rapid and Temporary Improvement of Depression and Anxiety Observed Following Niraparib Administration: A Case Report
by: Jewett, Benjamin E., et al.
Published: (2020)

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
by: Jing Ni, et al.
Published: (2021-05-01)

Current neoadjuvant treatment options for HER2 positive breast cancer
by: Abdel-Razeq H, et al.
Published: (2011-08-01)

Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma
by: Chen, J., et al.
Published: (2022)

Severe haematological toxicities in relapsed ovarian cancer treated with olaparib or niraparib: an Italian cost-minimization analysis
by: Carlo Lazzaro, et al.
Published: (2019-05-01)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
by: Q. P. Janssen, et al.
Published: (2021-03-01)

Emphasis on neoadjuvant therapy for “resectable” pancreatic cancer
by: LIU Chang
Published: (2015-05-01)

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
by: Aurélien Lambert, et al.
Published: (2021-09-01)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
by: Yong Jae Lee, et al.
Published: (2020-03-01)

Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes
by: Liu S, et al.
Published: (2020-05-01)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018-09-01)

Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
by: Roberto J. Arai, et al.
Published: (2018-06-01)

Moving Mountains—The BRCA1 Promotion of DNA Resection
by: Ruth M. Densham, et al.
Published: (2019-09-01)

Outcomes of neoadjuvant chemotherapy in resectable, borderline resectable and locally advanced pancreatic cancer
by: Kamil D. Dalgatov, et al.
Published: (2021-08-01)

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
by: Jinyu Meng, et al.
Published: (2021-10-01)

Post neoadjuvant HER2 treatment: real world data from a multicentric cohort
by: P. Luz, et al.
Published: (2021-04-01)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
by: Chang-Jun Wang, et al.
Published: (2020-11-01)

Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer: clinical outcomes with the 'CROSS-regimen' in daily practice
by: Cloos-V Balen, M., et al.
Published: (2022)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
by: G. Griguolo, et al.
Published: (2021-03-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
by: Katherine V. Trinh, et al.
Published: (2020-09-01)

HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
by: Tamera J. Lillemoe, et al.
Published: (2021-01-01)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
by: Qiancheng Hu, et al.
Published: (2019-07-01)

Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials
by: Tarun Kumar, et al.
Published: (2020-03-01)

BRCA1 mRNA expression levels as an predictor of response to neoadjuvant chemotherapy in breast cancer
by: M. M. Tsyganov, et al.
Published: (2018-05-01)

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
by: Tatiana V. Gorodnova, et al.
Published: (2021-02-01)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
by: Siddharth Iyengar, et al.
Published: (2021-09-01)

Cannot write session to /tmp/vufind_sessions/sess_ri9548mc0l9ikvdolgdosk0jvr